Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma metabolomics after single Nemolizumab dose in atopic dermatitis
jRCT1050240115Active, not recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of nemolizumab in atopic dermatitis (AD) (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Temporal variation of plasma metabolites after single nemolizumab administration, Metabolite-based clustering of atopic dermatitis patients and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT1050240115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050240115.